None listed
Conditions
Brief summary
The HUNTER trial is a randomised clinical trial in Australian non-tertiary special care nurseries comparing the efficacy and safety of high-flow nasal cannulae (HFNC) to continuous positive airway pressure (CPAP) as primary respiratory support after birth for preterm and term infants with early respiratory distress.
Interventions
High-flow nasal cannulae (HFNC) - heated, humidifed gas (blended air/oxygen) delivered at gas flows between 6-8 Litres per minute via the Fisher & Paykel 'Optiflow Junior' circuit and prongs. HFNC will be weaned/ceased when the infant has no supplemental oxygen requirement, or has required <25% supplemental oxygen for >24 hours.
Sponsors
Newborn Research Centre, The Royal Women's Hospital
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
0 to 24 Hours
Healthy volunteers
No
Inclusion criteria
1. Gestational age 31 weeks' or above by best obstetric estimate 2. Birth weight >1200 grams 3. Age <24 hours 4. Admitted to the special care nursery of a participating centre 5. Require non-invasive breathing support after admission to the special care nursery, or require supplemental oxygen to maintain peripheral oxygen saturation 91-95% for >1 hour
Exclusion criteria
1. After admission to the SCN, the infants has already received >4 hours of CPAP 2. Previous endotracheal intubation and positive pressure ventilation, or imediate need for endotracheal intubation as determined by the treating paediatrician 3. Known major congenital abnormality which may impact upon the infant's condition after birth (eg. complex congenital cardiac disease, upper airway obstruction, gastrointestinal malformations) 4. Any infant who is judged by their paediatrician to require transfer to a tertiary hospital for ongoing care
Outcome results
None listed